Compare SACH & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SACH | CTSO |
|---|---|---|
| Founded | 2010 | 1997 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 45.9M |
| IPO Year | N/A | N/A |
| Metric | SACH | CTSO |
|---|---|---|
| Price | $1.03 | $0.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $2.00 | ★ $5.38 |
| AVG Volume (30 Days) | ★ 127.1K | 79.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 19.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $7.29 |
| Revenue Next Year | $1.73 | $8.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.60 |
| 52 Week High | $1.35 | $1.39 |
| Indicator | SACH | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 42.55 |
| Support Level | $0.99 | $0.62 |
| Resistance Level | $1.06 | $0.67 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 43.75 | 6.82 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.